Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Moodys
Colorcon
AstraZeneca
McKesson

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fasiglifam

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Fasiglifam: Patents, clinical trial progress, indications

Fasiglifam is an investigational drug.

There have been 10 clinical trials for Fasiglifam. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2012.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Takeda and [disabled in preview].

There are thirty-two US patents protecting this investigational drug and two hundred and ninety-two international patents.

Recent Clinical Trials for Fasiglifam
TitleSponsorPhase
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on HemodialysisTakedaPhase 3
Fasiglifam 25 mg BID vs 50 mg QDTakedaPhase 2
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 DiabetesTakedaPhase 3

See all Fasiglifam clinical trials

Clinical Trial Summary for Fasiglifam

Top disease conditions for Fasiglifam
Top clinical trial sponsors for Fasiglifam

See all Fasiglifam clinical trials

US Patents for Fasiglifam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fasiglifam   See Pricing Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   See Pricing
Fasiglifam   See Pricing Heterocyclic compounds CADILA HEALTHCARE LIMITED (Ahmedabad, Gujarat, IN)   See Pricing
Fasiglifam   See Pricing Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   See Pricing
Fasiglifam   See Pricing Heterocyclic compounds having cholesterol 24-hydroxylase activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP)   See Pricing
Fasiglifam   See Pricing 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP)   See Pricing
Fasiglifam   See Pricing Medical use of pharmaceutical combination or composition Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   See Pricing
Fasiglifam   See Pricing Heterocyclic compounds CADILA HEALTHCARE LIMITED (Ahmedabad, Gujarat, IN)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fasiglifam

Drugname Country Document Number Estimated Expiration Related US Patent
Fasiglifam Australia 2011249722 2030-05-05   See Pricing
Fasiglifam Brazil 112012028136 2030-05-05   See Pricing
Fasiglifam Canada 2797310 2030-05-05   See Pricing
Fasiglifam Chile 2012003053 2030-05-05   See Pricing
Fasiglifam China 102946875 2030-05-05   See Pricing
Fasiglifam China 107961377 2030-05-05   See Pricing
Fasiglifam Eurasian Patent Organization 201201508 2030-05-05   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Moodys
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.